ConductScience.org, home

Paper17522506

A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma.

Lo CM and 7 others. Ann Surg, 2007. Cited by 198 papers, by iCite.

Cite this record

ConductScience Library. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Papers, record 17522506. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17522506

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma.
PubMed
Journal
Ann Surg
PubMed
Year
2007
PubMed
Publication types
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
198
iCite
Relative citation ratio, by iCite
4.66
iCite
Revised in PubMed
2024-11-27
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lo CMChung Mau
2Liu CLChi Leung
3Chan SCSee Ching
4Lam CMChi Ming
5Poon RTRonnie T P
6Ng IOIrene O L
7Fan STSheung Tat
8Wong JJohn

Source PubMed

Download CSV of authors

Topics23

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Carcinoma, HepatocellularMajor topic
Interferon-alphaMajor topic
Liver NeoplasmsMajor topic
Adult
Aged
Chemotherapy, Adjuvant
Chi-Square Distribution
Combined Modality Therapy
Female
Hepatectomy
Hepatitis B
Humans
Interferon alpha-2
Male
Middle Aged
Neoplasm Staging
Prognosis
Proportional Hazards Models
Recombinant Proteins
Statistics, Nonparametric
Survival Rate
Treatment Outcome

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT01681446Adjuvant IFN-α for Patients Underwent Curative Surgery for HCC With a Low miR-26 ExpressionBackground

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in17522507Interferon: the magic bullet to prevent hepatocellular carcinoma recurrence after resection?https://conductscience.org/library/papers/17522507

Source PubMed

Download CSV of comments and corrections

References33

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
110077043Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths.Ann Surg1999https://conductscience.org/library/papers/10077043PubMed
28392955Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma.Gastroenterology1993https://conductscience.org/library/papers/8392955PubMed
310869287High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential.Hepatology2000https://conductscience.org/library/papers/10869287PubMed
410051505Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection.Hepatology1999https://conductscience.org/library/papers/10051505PubMed
511772139Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C.Drugs2001https://conductscience.org/library/papers/11772139PubMed
68628336Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group.N Engl J Med1996https://conductscience.org/library/papers/8628336PubMed
77539237Hepatocellular carcinoma: surgical resection versus surgical resection combined with pre- and post-operative locoregional immunotherapy-chemotherapy. A prospective randomized study.Anticancer Res1995https://conductscience.org/library/papers/7539237PubMed
810694562Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis.J Clin Oncol2000https://conductscience.org/library/papers/10694562PubMed
98224650Multiple hepatocellular carcinomas at the early stage have different clonality.Gastroenterology1993https://conductscience.org/library/papers/8224650PubMed
1010931448Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma.Cancer2000https://conductscience.org/library/papers/10931448PubMed
1112644537Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis.J Natl Cancer Inst2003https://conductscience.org/library/papers/12644537PubMed
129151912Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study.Semin Oncol1997https://conductscience.org/library/papers/9151912PubMed
1311413528Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials.Cancer2001https://conductscience.org/library/papers/11413528PubMed
1412372721Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials.Lancet Oncol2002https://conductscience.org/library/papers/12372721PubMed
158383088Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial.Hepatology1993https://conductscience.org/library/papers/8383088PubMed
168618580Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.N Engl J Med1996https://conductscience.org/library/papers/8618580PubMed
173019535Clonal origin of human hepatoma determined by integration of hepatitis B virus DNA.Cancer Res1986https://conductscience.org/library/papers/3019535PubMed
1812823597Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.J Viral Hepat2003https://conductscience.org/library/papers/12823597PubMed
1914716774Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors.Cancer2004https://conductscience.org/library/papers/14716774PubMed
206088019Primary liver cancer. An Eastern Cooperative Oncology Group Trial.Cancer1984https://conductscience.org/library/papers/6088019PubMed

See all 33 referencesDownload CSV of references

Cited by89

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 198 citations.

PMIDTitleJournalYearIn PapersSource
41312046Pegylated Interferon-α-Induced Functional Cure for Special Populations with Chronic Hepatitis B Virus Infection: Current Trends, Challenges and Prospection.Drug Des Devel Ther2025https://conductscience.org/library/papers/41312046PubMed
39212922Hepatocellular Carcinoma: Surgical Management and Evolving Therapies.Cancer Treat Res2024https://conductscience.org/library/papers/39212922PubMed
38779519Adjuvant Therapy for Hepatocellular Carcinoma After Curative Treatment: Several Unanswered Questions.J Clin Transl Hepatol2024https://conductscience.org/library/papers/38779519PubMed
38733195[Research progress on the effect of hepatitis B virus DNA integration on antiviral therapy].Zhonghua Gan Zang Bing Za Zhi2024https://conductscience.org/library/papers/38733195PubMed
38622688Interferon-α stimulates DExH-box helicase 58 to prevent hepatocyte ferroptosis.Mil Med Res2024https://conductscience.org/library/papers/38622688PubMed
38188092Harmine Hydrochloride Induces G2/M Cell Cycle Arrest and Apoptosis in SK-Hep1 Hepatocellular Carcinoma Cells by Regulating Mitogen-Activated Protein Kinases and the PI3K/AKT Pathway.Prev Nutr Food Sci2023https://conductscience.org/library/papers/38188092PubMed
38165580Interferon therapy improves survival in patients with hepatitis B virus-related hepatocellular carcinoma after curative surgery: a meta-analysis.Hepatol Int2024https://conductscience.org/library/papers/38165580PubMed
38164272Long-Term Survival and Cancer Risk in the Hepatitis C Virus-Infected Patients After Antiviral Treatment: A Nationwide Cohort Study.J Cancer2024https://conductscience.org/library/papers/38164272PubMed
37958294Hepatocellular Carcinoma: Surveillance, Diagnosis, Evaluation and Management.Cancers (Basel)2023https://conductscience.org/library/papers/37958294PubMed
37901768Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition).Liver Cancer2023https://conductscience.org/library/papers/37901768PubMed
37730533Network meta-analysis of adjuvant treatments for patients with hepatocellular carcinoma after curative resection.BMC Gastroenterol2023https://conductscience.org/library/papers/37730533PubMed
37382760
Perioperative safety, oncologic outcome, and risk factors of salvage liver resection for initially unresectable hepatocellular carcinoma converted by transarterial chemoembolization plus tyrosine kinase inhibitor and anti-PD-1 antibody: a retrospective multicenter study of 83 patients.
Hepatol Int2023https://conductscience.org/library/papers/37382760PubMed
37139151Adjuvant therapy following curative treatments for hepatocellular carcinoma: current dilemmas and prospects.Front Oncol2023https://conductscience.org/library/papers/37139151PubMed
36968218Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial.JHEP Rep2023https://conductscience.org/library/papers/36968218PubMed
36926237Current status and prospect of treatments for recurrent hepatocellular carcinoma.World J Hepatol2023https://conductscience.org/library/papers/36926237PubMed
36909127Human Epidermal Growth Factor Receptor 2 (HER2) Expression by Immunohistochemistry and Its Clinical Significance in Hepatocellular Carcinoma: A Single-Center Analysis.Cureus2023https://conductscience.org/library/papers/36909127PubMed
36645648Adjuvant anti-PD-1 antibody for hepatocellular carcinoma with high recurrence risks after hepatectomy.Hepatol Int2023https://conductscience.org/library/papers/36645648PubMed
36187393Advances in postoperative adjuvant therapy for primary liver cancer.World J Gastrointest Oncol2022https://conductscience.org/library/papers/36187393PubMed
35459855The combination of PD-1 blockade with interferon-α has a synergistic effect on hepatocellular carcinoma.Cell Mol Immunol2022https://conductscience.org/library/papers/35459855PubMed
35300207Postoperative Adjuvant Transarterial Chemoembolization Plus Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma: a Multicentre Retrospective Study.J Hepatocell Carcinoma2022https://conductscience.org/library/papers/35300207PubMed

See all 89 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
IFNA23440PubTator's text mininghttps://conductscience.org/library/genes/3440

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17522506

GET https://conductscience.org/api/papers/v1/17522506/references?page=2